Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Depreciation & Amortization (CF) (2023 - 2025)

Mangoceuticals' Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $255.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% to $255.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1013.0, a 89.8% decrease, with the full-year FY2025 number at $1012.0, down 89.81% from a year prior.
  • Depreciation & Amortization (CF) hit $255.0 in Q4 2025 for Mangoceuticals, roughly flat from $256.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for MGRX hit a ceiling of $12515.0 in Q3 2023 and a floor of $250.0 in Q1 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $3823.8 across 3 years, with a median of $3457.0 in 2024.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 2.33% in 2024 and later crashed 95.98% in 2025.
  • Tracing MGRX's Depreciation & Amortization (CF) over 3 years: stood at $6292.0 in 2023, then tumbled by 95.95% to $255.0 in 2024, then changed by 0.0% to $255.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for MGRX at $255.0 in Q4 2025, $256.0 in Q3 2025, and $252.0 in Q2 2025.